DANIELLI, RICCARDO
 Distribuzione geografica
Continente #
NA - Nord America 1.172
EU - Europa 892
AS - Asia 183
AF - Africa 2
OC - Oceania 1
SA - Sud America 1
Totale 2.251
Nazione #
US - Stati Uniti d'America 1.168
IE - Irlanda 231
GB - Regno Unito 195
CN - Cina 118
IT - Italia 107
RU - Federazione Russa 98
SE - Svezia 69
DE - Germania 57
UA - Ucraina 44
FR - Francia 38
SG - Singapore 36
ES - Italia 19
FI - Finlandia 19
VN - Vietnam 12
KR - Corea 8
BE - Belgio 3
PL - Polonia 3
AZ - Azerbaigian 2
CH - Svizzera 2
HR - Croazia 2
IN - India 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
AU - Australia 1
BG - Bulgaria 1
BO - Bolivia 1
CA - Canada 1
CI - Costa d'Avorio 1
EE - Estonia 1
GR - Grecia 1
HK - Hong Kong 1
JP - Giappone 1
LK - Sri Lanka 1
MX - Messico 1
SA - Arabia Saudita 1
TR - Turchia 1
ZA - Sudafrica 1
Totale 2.251
Città #
Fairfield 232
Dublin 231
Southend 182
Ashburn 109
Woodbridge 100
Cambridge 91
Houston 91
Seattle 85
Wilmington 78
Siena 50
Jacksonville 44
Chandler 43
Ann Arbor 39
Beijing 35
Princeton 33
Shanghai 30
Singapore 25
Málaga 19
New York 18
San Mateo 18
Helsinki 17
Dearborn 14
San Diego 13
Dong Ket 11
Moscow 10
Nanjing 10
Palermo 7
San Francisco 6
Yongsan-gu 6
London 5
Venezia 5
Boardman 4
Hefei 4
Labico 4
Nanchang 4
Norwalk 4
Asciano 3
Brussels 3
Düsseldorf 3
Kunming 3
Pistoia 3
Redwood City 3
Baku 2
Bratislava 2
Changsha 2
Falls Church 2
Jinan 2
Milan 2
Saha-gu 2
Santa Clara 2
Sesto Fiorentino 2
Tianjin 2
Wandsworth 2
Zagreb 2
Zurich 2
Abidjan 1
Arezzo 1
Athens 1
Canberra 1
Chengdu 1
Chiswick 1
Colombo 1
Delhi 1
Ferentino 1
Figline Valdarno 1
Florence 1
Fremont 1
Guangzhou 1
Hebei 1
Hendon 1
Hong Kong 1
Hounslow 1
Hyderabad 1
Islington 1
Jiaxing 1
Johannesburg 1
Kilburn 1
La Paz 1
Lanzhou 1
Mexico City 1
Ningbo 1
Redmond 1
Reggio Calabria 1
Reston 1
Richmond 1
Riyadh 1
Rome 1
Scarperia 1
Shinjuku 1
Sofia 1
Stockholm 1
Tallinn 1
Torino 1
Toronto 1
Trieste 1
Vicenza 1
Warsaw 1
Wenzhou 1
Totale 1.764
Nome #
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 218
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 181
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 174
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy 174
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 130
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 129
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 117
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma 115
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 106
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies 104
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 104
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications 98
Immunotherapy targeting immune check-point(s) in brain metastases 98
Eruptive porokeratosis under nivolumab adjuvant treatment for melanoma 98
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study 91
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients 86
null 75
ICOS expression as immunologic marker in immune activating monoclonal antibodies 75
null 58
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study 37
Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial 29
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 27
Totale 2.324
Categoria #
all - tutte 8.449
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.449


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020643 0 0 0 0 70 67 157 112 88 70 34 45
2020/2021453 32 31 42 18 39 85 18 77 14 42 14 41
2021/2022259 19 38 23 5 11 12 14 14 13 32 28 50
2022/2023285 21 24 54 22 9 48 10 31 17 20 16 13
2023/2024350 12 7 59 13 7 81 132 4 0 1 16 18
2024/2025134 18 25 63 23 5 0 0 0 0 0 0 0
Totale 2.324